LOXO-292 Chemical Properties

Density 

1.36±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:20.0(Max Conc. mg/mL);38.05(Max Conc. mM)

form 

A crystalline solid

pka

14.00±0.29(Predicted)

InChI

InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

InChIKey

XIIOFHFUYBLOLW-UHFFFAOYSA-N

SMILES

C12=C(C#N)C=NN1C=C(OCC(O)(C)C)C=C2C1=CC=C(N2CC3CC(N3CC3=CC=C(OC)N=C3)C2)N=C1

LOXO-292 Usage And Synthesis

Uses

Selpercatinib is a highly selective, potent RET inhibitor, an oral drug used to treat cancers in people whose tumours have been altered (mutated or fused) in specific genes (RET stands for "rearrangement during transfection").

Side effects

Selpercatinib can cause serious side effects including liver toxicity, high blood pressure, heart rhythm changes due to prolongation of heart electrical activity (QT prolongation), bleeding, allergic reactions, impaired wound healing and harm to an unborn baby.

Selpercatinib may cause harm to a developing fetus or a newborn baby.

storage

Store at -20°C

Dosage

The recommended selpercatinib dose based on body weight is: (1) Less than 50 kg: 120 mg orally twice daily (2) 50 kg or greater: 160 mg orally twice daily

LOXO-292(2152628-33-4)Related Product Information

• Selumetinib
• Saracatinib
• LOXO-292
• LOXO-195
• 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)Methyl)benzoic acid
• 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine
• 2-Amino-6-bromopyridine
• Brigatinib
• Crizotinib
• 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
• Lorlatinib (PF-06463922)
• Olaparib
• Glecaprevir
• ABT-530
• NBQX DISODIUM SALT
• SU14813
• Futibatinib
• S-Ruxolitinib (INCB018424)